Lv31
273 积分 2021-05-10 加入
A randomized, double-blind, placebo-controlled, single, and multiple dose-escalation Phase I clinical trial to investigate the safety, pharmacokinetic, and pharmacodynamic profiles of oral S086, a novel angiotensin receptor-neprilysin inhibitor, in healthy Chinese volunteers
3小时前
已完结
Clinicopathological correlation of PD-L1 expression in primary and metastatic breast cancer and infiltrating immune cells
2天前
已完结
Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease
2天前
已完结
Sequelae of B-Cell Depleting Therapy: An Immunologist’s Perspective
2天前
已完结
Abstract CT029: Chemotherapy-free neoadjuvant regimen with durvalumab, trastuzumab and pertuzumab (DTP) in HER2-enriched early breast cancer: A prospective, open-label phase II trial
1个月前
已关闭
Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus
4个月前
已完结
Chronic Administration of Belimumab, a BLyS Antagonist, Decreases Tissue and Peripheral Blood B-Lymphocyte Populations in Cynomolgus Monkeys: Pharmacokinetic, Pharmacodynamic, and Toxicologic Effects
5个月前
已完结
A pre-clinical quantitative model predicts the pharmacokinetics/pharmacodynamics of an anti-BDCA2 monoclonal antibody in humans
6个月前
已完结
Contribution of mouse models in our understanding of lupus
6个月前
已完结
A Randomized, Placebo-Controlled, Phase 1 Study in Healthy Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN303, a Potent Dual BAFF/APRIL Antagonist for the Treatment of Autoimmune Cytopenias
7个月前
已完结
皖公网安备34019202002308
